Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Multi Cap Fund median (29 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 02 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. Nifty 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | ICICI Prudential Multicap Fund |
|---|---|
| 02 Jan 2013 | ₹100.00 |
| 21 Feb 2014 | ₹102.71 |
| 12 Apr 2015 | ₹161.31 |
| 31 May 2016 | ₹161.01 |
| 19 Jul 2017 | ₹195.91 |
| 07 Sep 2018 | ₹202.65 |
| 27 Oct 2019 | ₹185.08 |
| 15 Dec 2020 | ₹196.33 |
| 03 Feb 2022 | ₹242.78 |
| 25 Mar 2023 | ₹227.32 |
| 12 May 2024 | ₹336.52 |
| 01 Jul 2025 | ₹378.04 |
| 20 Aug 2026 | ₹394.28 |
| Metric | ICICI Prudential · Direct · IDCW NAV ₹65.53 Very High risk ★★★☆☆ | Category median Multi Cap Fund · 29 funds |
|---|---|---|
| +4.65% | +6.55% | |
| +12.84% | +13.71% | |
| +10.86% | +12.07% | |
| +8.00% | +9.16% | |
| +10.59% | +14.55% | |
| +11.36% | — | |
| +10.51% | +17.33% | |
| +9.19% | +14.39% | |
| +9.74% | +9.74% | |
| Risk | ||
| 14.52% | 15.40% | |
| 0.44 | 0.41 | |
| 0.58 | 0.54 | |
| -45.14% | -21.00% | |
| Nifty 500 | — | |
| +0.87% | +1.30% | |
| 0.96 | 1.03 | |
| 103.3% | 104.7% | |
| 102.0% | 99.6% | |
| 1.03% | 0.93% | |
| ₹17,214Cr | ₹4,007Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹100 | — | |
| ₹5.00K | — | |
| 45% | 53% | |
| Sharmila D'silva | — | |
| 02 Jan 2013 | — | |
| 163 | — | |
| 24.0% | — | |
| 2.6% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.